Recent advances in T cell biology have shed light on the role of T cell subsets in the pathogenesis of acute kidney injury (AKI). The purpose of this review is to harness our understanding of recent advances in T cell biology in tissue injury and repair and provide a mechanistic insight into the role of T cells in the inflammation of AKI.
INTRODUCTION
The incidence of acute kidney injury (AKI) has been steadily increasing in recent decades, and AKI causes significant morbidity and mortality in those who are affected [1] . Common causes of AKI include: sepsis, use of nephrotoxic drugs and conditions resulting in ischemia or hypoperfusion of the kidneys (cardiopulmonary bypass, hemorrhage, severe hypotension, etc.). Ischemia induces a complex series of events that lead to altered hemodynamics, tubular injury and inflammation. Early in the course of AKI, Sutton et al. [2] have proposed an 'extension phase' of ischemic AKI in which immune cells play a critical role. This proposal is based upon a long recognized feature that the kidney interstitial microenvironment is a fertile ground for innate immune cells such as dendritic cells and macrophages [3] , and following ischemia there is an accumulation and activation of immune cells in the damaged kidney [4] . CD3
þ T cells are prominent in the inflammatory infiltrate in human AKI [5] and accumulate in the kidney within 30 min to a few hours in murine models of AKI [6] [7] [8] [9] [10] . Studies in experimental AKI have demonstrated a causal role for certain types of T cells in promoting renal injury, whereas other studies have revealed protective roles for other T cell subsets (see below). Immune cells accumulate in the corticomedullary junction leading to vascular congestion, interstitial edema, and diminished nutrient and oxygen delivery.
T CELLS IN THE PATHOGENESIS OF EXPERIMENTAL ACUTE KIDNEY INJURY
The role of T cells in tissue injury is supported by several early studies [11] [12] [13] [14] [15] . Zwacka et al. [15] demonstrated an early role of T cells in mouse liver ischemia-reperfusion injury. In this mouse model of liver injury, T cells were detected maximally at 1 h post reperfusion [15] . Using T-cell deficient mice and/or adoptive transfer of T cells, T cells were found to be key mediators of inflammatory responses mediated by neutrophils [15] . In a warm ischemiareperfusion model, using specific markers for inflammatory cells, macrophages, CD4
þ T cells and CD8 þ T cells have been identified in renal tissue [16] . The appearance of these inflammatory cells began as early as 1 h after ischemia-reperfusion and appeared to peak at around 5 days [16] . Several other studies have demonstrated that CD4 þ T cells are involved in kidney ischemia-reperfusion injury (IRI) [17] [18] [19] [20] [21] . However, conventional CD4 þ T cells are thought to play an obligatory role in antigenspecific, cognate immunity that requires 2-4 days for T cell processing. The kinetics of conventional T cell activation is inconsistent with the rapid, innate immune response following IRI. By contrast, natural killer T (NKT) cells are a T cell sublineage [22] known to participate in innate immunity and may contribute to the early events in IRI (described below).
HOW ARE T CELLS ACTIVATED?
Both kidney parenchymal cells and bone marrowderived cells make up the renal interstitial microenvironment [3] . Under normal conditions, members of the mononuclear phagocytic system make up the largest population of immune cells in the kidney [23] [24] [25] . Many of these mononuclear phagocytes are dendritic cells, based on the expression of phenotypic markers [23] [24] [25] . Dendritic cells are professional antigen presenting cells (APCs), specialized for activating T cells. In addition, the uninjured kidney also contains several different types of T cells [CD4
þ , CD4 -CD8 -, NKT and regulatory T cells (Tregs)] [26] . Following ischemia-reperfusion, vascular endothelial cells and renal tubular epithelial cells are injured and play a critical role in initiating and facilitating inflammation in response to kidney injury [27] . After injury, damageassociated molecular patterns are released by dead or dying cells in the kidney, and these molecules activate dendritic cells through interaction with toll-like receptors and a variety of other proinflammatory receptors [28] . Dendritic cells in turn upregulate positive costimulatory ligands, produce proinflammatory cytokines and activate both innate and adaptive immune cells (including T cells) [29] [30] [31] . The injured tubular epithelial cells produce chemokines to attract circulating leukocytes and renal vascular endothelial cells upregulate expression of adhesion molecules to facilitate extravasation of leukocytes [27, [32] [33] [34] . In summary, the kidney interstitium is inhabited by professional APCs and T cells under normal circumstances and after injury multiple cells contribute to the establishment of a proinflammatory microenvironment.
Common features of T cells are the expression of the T cell receptor (TCR) and CD3, which is a protein complex that transduces signals from the TCR into the T cell. The TCR allows T cells to recognize specific antigens (peptides, glycolipids, etc.) presented by APCs. At the time of antigen presentation, additional signals provided by APCs influence the type of T cell response that will develop. Costimulation is one such signal provided through cell surface receptors and ligands on APCs and T cells. Positive costimulation through CD28 on T cells and CD80 or CD86 expressed on APCs reinforces the TCR signal and promotes cytokine production and T cell proliferation [35] . On the other hand, negative costimulation through inhibitory receptors on T cells [e.g. cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death 1 (PD-1)] antagonizes the activation of T cells [35] . Some APCs also produce cytokines such as interleukin (IL)-12 and IL-23 that promote and direct the T cell response to antigens.
Nitric oxide is an important signaling molecule and critically related to the pathogenesis of AKI [36] . Depending on its concentration and duration of action nitric oxide can promote survival or death of endothelial and epithelial cells of the kidney [36] . In addition, nitric oxide and inducible nitric oxide synthase (iNOS) can influence the immune response. For example, nitric oxide is required for processing of certain antigens intracellularly prior to presentation to T cells by APCs [37] ; however, iNOSexpressing dendritic cells were shown to inhibit T cell activation in an autoimmune myocarditis model [38] . In an ischemic AKI model, iNOSexpressing macrophages contribute to kidney injury, but the role of T cells in this process has not been studied [39] . Given the complexity of the actions of nitric oxide in different contexts and cell types, the influence of nitric oxide on T cell action during AKI requires further study to be understood.
KEY POINTS
Some T cells use proinflammatory cytokines (e.g. IFN-g) and chemokines (e.g. CXCL1) to promote acute renal injury.
Tregs promote protection from injury by production of IL-10 and expression of anti-inflammatory proteins on their cell surface.
Activation of endogenous Tregs or cell-based therapy using Tregs may be used in the treatment of AKI.
NKT cells can induce renal inflammation and injury or protect from it depending on the context of their activation.
The family of T cells is large, containing multiple subtypes of lymphocytes with vastly different characteristics. CD3
þ T helper (Th) cells recognize peptide antigens and primarily coordinate and promote the activity of other inflammatory cells. Depending on the context of their activation (costimulation and cytokine milieu), naive CD4 T cells can differentiate into: Th1 cells that produce interferon g (IFN-g), Th2 cells that produce IL-4, Th17 cells that produce IL-17, or several other types of Th cells [40] . On the other end of the spectrum of CD3 þ CD4 þ lymphocytes are the Tregs that suppress the activation of most other proinflammatory cells [41] . Tregs are identified by the expression of the transcription factor forkhead box P3 (FoxP3) [42] [43] [44] and use a variety of mechanisms to inhibit other immune cells. These include production of anti-inflammatory cytokines (e.g. IL-10) or molecules (e.g. adenosine) or cell contact-dependent mechanisms (CTLA-4, cyclic adenosine monophosphate transfer, etc.) [41] . CD3 þ CD8 þ cytotoxic T cells recognize antigens generated by cancerous or infected cells and kill target cells using perforin, granzymes and/or Fas ligand. NKT cells make up a relatively small proportion of T cells but are robust producers of Th1 and Th2 cytokines. There are two main groups of NKT cells: type I, invariant NKT cells that express very similar TCRs and recognize glycolipid antigens (e.g. a-galactosylceramide) and type II NKT cells that express more diverse TCRs and recognize other lipid antigens (e.g. sulfatide). Depending on the setting, NKT cells can perform proinflammatory or anti-inflammatory functions [45, 46] . Thus, T cells are a large family of lymphocytes with diverse functions and phenotypes.
T CELLS THAT PROMOTE INJURY
As mentioned above, CD4
þ T cells were initially identified as the primary type of pathogenic T cells in experimental AKI. As there are multiple types of CD4 þ T cells, identification of the responsible subset(s), and the ways in which they affect renal function during AKI, is critical to developing therapeutics based on the role of T cells in injury. There are numerous mechanisms by which T lymphocytes can induce injury to other cells and promote renal dysfunction ( Fig. 1) [47, 48] . The requirement for IFN-g made by T cells suggests that Th1 cells are involved. However, when signal transducers and activators of transcription 4 knockout mice (which cannot mount Th1 responses) were compared with wild-type mice after IRI, only a mild reduction in serum creatinine was observed, and no difference in tissue damage was noted between groups [49] . Also, the time required for a conventional Th1 response to develop (3 or more days) is not congruent with the inflammation observed in experimental AKI (beginning within hours). In contrast, NKT cells (some but not all of which are CD4 þ [46] ) once activated can produce large amounts of IFN-g within hours [45, 46] . In support of this, adoptive transfer of a-galactosylceramide (glycolipid antigen specific for type I NKT cells) loaded dendritic cells prior to subthreshold ischemic injury exacerbates renal injury and dysfunction in wild-type mice [33,50 && ], but not NKT-cell deficient or IFN-g-deficient mice [33] . It should be noted that that several studies have observed protective phenotypes in mice either lacking type I NKT cells, or in which glycolipid antigen presentation has been blocked [8, 33] , whereas another study did not report protection in type I NKT-cell deficient mice [51] . The reasons for this discrepancy are not known, but could be because of the differences in gut flora between different institutions as gut flora has been shown to modulate type I NKT cell phenotype [52] .
Some other recent studies have focused more on the mechanisms of activation, and mediators produced by CD4 þ T cells in experimental AKI rather than identification of specific subsets. For example, Akcay et al. [48] reported that IL-33 released by renal cells injured by cisplatin activates CD4 þ T cells and promotes their recruitment to the kidney. IL-33 promoted chemokine (C-X-C motif) ligand 1 (CXCL1) production by CD4 þ T cells in the kidney and in vitro [48] , and CXCL1 is known to promote neutrophil recruitment and can directly induce apoptosis [53] . Other recent studies have focused on T-cell immunoglobulin and mucin domain-containing protein-1 [(TIM-1); also known as kidney injury molecule-1 (KIM-1)] expressed on T cells in experimental AKI models [54, 55] . TIM-1 is expressed on activated CD4 þ T cells as well as injured renal tubular epithelial cells [56 & ]. Using a blocking antibody to TIM-1 [rat monoclonal TIM-1 antibody (RMT1-10)] was protective against both cisplatin [54] and ischemia-reperfusion [55] induced renal injury in mice. The protective effect was lost in both studies if the antibodies were administered to recombination activating gene-1 (RAG-1) knockout mice (which lack T and B cells) prior to injury [54, 55] . Adoptive transfer of splenocytes (containing T and B cells) into RAG-1 knockout recipients restored the protective effect of RMT1-10, demonstrating the role of immune cells in protection from IRI [55] . As pointed out by Ichimura et al. [56 & ], there are several caveats of these studies to be considered before concluding that TIM-1 on CD4 þ T cells is a target to be blocked therapeutically. These include the expression of TIM-1 on immune cells other than just CD4
þ T cells, possible stimulatory action of the RMT1-10 antibody on TIM-1 and the very high expression of TIM-1/KIM-1 on tubular epithelial cells vs. intrarenal immune cells after injury (see [56 & ] and references therein). In summary, numerous studies support a pathogenic role for T cells in AKI. Progress toward understanding the identity of the T cells involved and the mechanisms by which they promote injury is progressing at a modest pace. Factors hindering progress include the ever growing awareness of the heterogeneity and plasticity of T cell subsets [40] and limitations of the current mouse models and experimental reagents. Persistence and innovative ideas/technologies are needed to advance our knowledge of T cell-based targets for inhibition to ameliorate AKI.
T CELLS THAT PROTECT FROM INJURY OR PROMOTE REPAIR
Research has been progressing more rapidly on the recently discovered protective role of several types of T cells in AKI models. Several subsets of T cells show promise as potential therapeutic agents themselves (as cell-based immunotherapies) or as targets for pharmacological enhancement.
Regulatory T cells
Tregs provide a balance to proinflammatory immune cells by using multiple mechanisms to suppress inflammation (Fig. 2) [41, 57] . In 2009, the role of endogenous Tregs to protect against kidney IRI [58] and promote recovery from ischemic injury [59, 60] was identified. Since then the critical role for Tregs in the protection afforded by renal ischemic preconditioning has been demonstrated [61, 62] . Furthermore, in a nephrotoxic cisplatin-AKI model endogenous Tregs were also shown to protect from injury [63] . Adoptive transfer of isolated Tregs prior to ischemia or cisplatin markedly protects mice from renal dysfunction and tissue injury [58, 62, 63, 64 && ]. In addition, adoptive transfer of Tregs after injury accelerates repair and restoration of renal function [59] . Importantly, Treg adoptive transfers have been successfully performed in humans [65] [66] [67] , suggesting this type of therapy could be used clinically for AKI.
An alternative approach is to target endogenous Tregs to promote their proliferation, activity or trafficking to enhance their ability to protect the kidney or promote recovery from injury. Recently, numerous agents that target Tregs in vivo have been utilized in models of AKI with very encouraging results. The sphingosine kinase inhibitor dimethylsphingosine (DMS) protects against IRI in mice by promoting Treg recruitment to the kidney very quickly during reperfusion [68 & ]. A second sphingosine kinase inhibitor did not replicate this protection [68 & ], suggesting the enhanced Treg trafficking is mediated by a currently unknown mechanism of action for DMS. CTLA-4 blockade negated the protective effect of DMS in this study suggesting that Tregs utilize CTLA-4 to protect the kidney [68 & ]. Through CTLA-4, Tregs interact with dendritic cells to downregulate costimulatory molecule expression, and thus inhibit their ability to promote inflammation [69] . In another study, the protective effect of FTY720, a sphingosine-1-phosphate analog, on kidney IRI was shown to require Tregs [70] . Interestingly, bee venom injections increased Treg numbers in the spleen of mice and enhanced the trafficking of Tregs to the kidney shortly after cisplatin administration [71 && ]. Bee venom injections reduced renal dysfunction and injury caused by cisplatin in control mice, but not mice in which Tregs were depleted [71 && ]. In support of the feasibility of this therapy in cancer patients, bee venom had no effect on cisplatin's anticancer effects in their mouse model [71 && ]. In other disease models, IL-2/anti-IL-2 complexes protect from inflammatory injury by inducing Treg proliferation in vivo [72] . Kim et al. [73 && ] used this technique in mice and nicely demonstrated that IL-2/anti-IL-2 complexes can be used to prevent renal IRI and promote recovery from IRI if given after injury. Importantly, IL-2/ anti-IL-2 complexes significantly reduced renal fibrosis at 28 days after injury even when treatment was started 1 day after the ischemic insult [73 && ]. Finally, mesenchymal stem cell (MSC) therapy for AKI, which is currently being studied in several clinical trials (NCT00733876, NCT01275612), was shown to depend partially on the interaction between MSCs and Tregs in the spleens of recipient mice, as depletion of Tregs or splenectomy reduced the ability of MSCs to protect the kidney in this experimental IRI model [74 & ].
Natural killer T cells
NKT cells have the unique ability to produce Th1 (IFN-g) and/or Th2 (IL-10 and IL-4) cytokines rapidly and may promote or inhibit immune-mediated renal injury. Yang et al. [51] found that adoptive transfer of activated type II NKT cells (those which respond to the lipid antigen sulfatide) inhibited renal injury induced by ischemia-reperfusion. To offer protection, the NKT cells needed to traffic into the injured kidney [51] . In-vitro coculture experiments revealed that suflatide-activated NKT cells suppress hypoxia-induced tubular epithelial cell death in an IL-10-dependent manner [51] . [76] and may represent an effective way to target intrinsic T cells in AKI.
Splenic T cells
The spleen is a rich source of immune cells including T cells. Recent studies suggest that the spleen plays an important role in modulating organ ischemia-reperfusion. Evidence for the importance of the spleen in protecting organs comes from studies of preconditioning [77] and ischemia reperfusion to the kidney [78] . In these studies, splenectomy increases the injury or inflammation in organs subjected to ischemia-reperfusion or in distant organs [77, 78] . The mechanism for this effect is unknown, however recent studies by Gigliotti et al. 
CONCLUSION
The role of T cells in AKI has become much more complicated than originally envisioned. Some progress has been made in understanding the detrimental mechanisms of T cells in promoting injury and a previously unrecognized protective role of some T cell subsets has emerged. The complexity of the T cell family and the characteristics of T cells that are yet unknown make this a challenging area of investigation. However, as our understanding of how T cells modulate renal injury grows this should facilitate development of specifically targeted therapies to protect the kidney without causing unwanted global immunosuppression.
